Empa 25mg (10Pcs)

Empa 25 is indicated in:

As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

Pharmacology

Empagliflozin is an inhibitor of the sodium-glucose co-transporter-2 (SGLT-2). The SGLT2 co-transporters in the kidney are responsible for glucose reabsorption from the glomerular filtrate. SGLT2 inhibition has a glucuronic action, inhibiting renal absorption and lowering the renal glucose threshold, leading to higher glucose excretion. It also helps with weight loss and lowers blood pressure, as well as lowers hyperglycemia.

Dosage & Administration 

The recommended dose of Empagliflozin is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empagliflozin, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empagliflozin is recommended.

Interaction

Empagliflozin co-administration with diuretics resulted in increased urine volume.

Insulin or Insulin Secretagogues: Taking Empagliflozin together with insulin or insulin secretagogues raises the risk of hypoglycemia.

Positive Urine Glucose Test: In patients on SGLT2 inhibitors, monitoring glycemic control with urine glucose tests is not suggested since SGLT2 inhibitors enhance urinary glucose excretion, resulting in positive urine glucose tests. Use different strategies to keep track of your glycemic control.

Contraindications

Patients having a history of serious allergic reactions to Empagliflozin or any of its constituents, severe renal impairment, end-stage renal disease, or dialysis should not take Empagliflozin.

Side Effects

The most common adverse reactions associated with Empa 25 are urinary tract infections and female genital mycotic infections. Other common side effects include dehydration, hypotension, weakness, dizziness, and increased thirstiness.

Pregnancy & Lactation

Empa 25 has not been studied in pregnant women in a sufficient and well-controlled manner. Only if the possible benefit outweighs the risk to the fetus should empagliflozin be used during pregnancy. Empa 25 is not known to be excreted in human milk. It's not a good idea to do it if you're breastfeeding.

Precautions & Warnings

Renal function should be checked before starting Empagliflozin and then every few months after that. Patients with an eGFR of less than 45 ml/min/1.73 m2 should not start empagliflozin. Patients with an eGFR greater than or equal to 45 ml/min/1.73 m2 do not require dose adjustments.

Therapeutic Class

Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors.

Storage Conditions

Do not store at temperatures above 30°C. Keep out of children's reach.